Your browser doesn't support javascript.
loading
The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
Lallo, Alice; Frese, Kristopher K; Morrow, Christopher J; Sloane, Robert; Gulati, Sakshi; Schenk, Maximillian W; Trapani, Francesca; Simms, Nicole; Galvin, Melanie; Brown, Stewart; Hodgkinson, Cassandra L; Priest, Lynsey; Hughes, Adina; Lai, Zhongwu; Cadogan, Elaine; Khandelwal, Garima; Simpson, Kathryn L; Miller, Crispin; Blackhall, Fiona; O'Connor, Mark J; Dive, Caroline.
Afiliação
  • Lallo A; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Frese KK; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Morrow CJ; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Sloane R; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Gulati S; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Schenk MW; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Trapani F; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Simms N; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Galvin M; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Brown S; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Hodgkinson CL; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Priest L; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Hughes A; Oncology Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Lai Z; Oncology Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Waltham, Massachusetts.
  • Cadogan E; Oncology Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
  • Khandelwal G; RNA Biology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Simpson KL; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Miller C; RNA Biology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom.
  • Blackhall F; Institute of Cancer Sciences, University of Manchester, and Christie NHS Foundation Trust, Manchester, United Kingdom.
  • O'Connor MJ; Oncology Innovative Medicines and Early Development Biotech Unit, AstraZeneca, Cambridge, United Kingdom. caroline.dive@cruk.manchester.ac.uk mark.j.oconnor@astrazeneca.com.
  • Dive C; Clinical and Experimental Pharmacology Group, Cancer Research UK Manchester Institute, University of Manchester, Manchester, United Kingdom. caroline.dive@cruk.manchester.ac.uk mark.j.oconnor@astrazeneca.com.
Clin Cancer Res ; 24(20): 5153-5164, 2018 10 15.
Article em En | MEDLINE | ID: mdl-29941481
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Pirazóis / Pirimidinonas / Proteínas Tirosina Quinases / Proteínas Nucleares / Proteínas de Ciclo Celular / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Clin Cancer Res Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ftalazinas / Piperazinas / Pirazóis / Pirimidinonas / Proteínas Tirosina Quinases / Proteínas Nucleares / Proteínas de Ciclo Celular / Inibidores de Poli(ADP-Ribose) Polimerases Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Clin Cancer Res Ano de publicação: 2018 Tipo de documento: Article